1/ 🚀 AEBP2 isn’t what we thought. You were told that AEBP2 promotes PRC2 activity on chromatin. We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity. 👉 surl.li/cgwqcq A thread 🧵

We are delighted that @genesdev.bsky.social have selected our (w/ @adrianbracken.bsky.social) Weaver syndrome paper artwork as the November cover! This piece was made by my incredibly talented niece, Gina 'Dna Vinci' Ronan. @ucddublin.bsky.social @tcddublin.bsky.social @ucd-sbbs.bsky.social

Congratulations to the winners of the 2025 AEpiA Emma Whitelaw Publication Award! 🧬 1st place: @shellainasci.bsky.social 🧬 2nd place: @victoriasugrue.bsky.social 🧬 3rd place: @dairegannon.bsky.social This award recognises outstanding publications by ECRs in the field of epigenetics.

Absolutely delighted to share our preprint, using functional genomics to uncover a novel dependency in lymphoma that can overcome resistance to targeted therapy. Grateful to co-first author @jamesnolan.bsky.social and co-senior authors @conwayer1.bsky.social and @adrianbracken.bsky.social see👇

🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇 #CancerResearch #Epigenetics #Chromatin #Lymphoma

Great to see @jongminkmg.bsky.social’s preview of our work in @cp-molcell.bsky.social today! www.cell.com/molecular-ce...

Online Now: A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma Online now:

Our work identifying CBX4 as a potential therapeutic target for diffuse midline glioma has just been published in Molecular Cell! Check out co-first author @eimearlagan.bsky.social’s overview below.